Compare Abeona Therapeutics Inc (ABEO) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Lululemon Athletica Inc — how do they compare? Abeona Therapeutics Inc trades at $6.7 (market cap $373.32M), while Lululemon Athletica Inc trades at $113.59 (market cap $13.13B). The key difference: Lululemon Athletica Inc is far larger — about 35.2× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | LULU | |
|---|---|---|
Market Cap | $373.32M | $13.13B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $238.54 |
52-Week Low | $4.17 | $105.43 |
Enterprise Value | $228.22M | $13.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
LULU trades at $115.07, down 2.84% for the day, reflecting recent bearish sentiment amid a 45% year-to-date decline. The stock is near its pivot point of $115, with technical indicators signaling a bearish trend. Fundamentally, the company reported strong revenue of $10.59B in 2025 and a net income margin of 17.13%, with a low P/E of 9.36 suggesting undervaluation. Recent news highlights board settlement with founder Chip Wilson but also cultural missteps in China and a class-action lawsuit over tariff costs.
The outlook is mixed: attractive valuation and international growth potential contrast with North American weakness and brand reputation risks. Analyst consensus is a $130.53 price target with 41% buy ratings, but near-term volatility persists. Key risks include execution on guidance, competitive pressures, and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
